Skip to content

RYAN changes

Pick any two versions below to diff them.

View the full Nov 15, 2026 version
Price
$47.07
Discount category
Close to intrinsic value
Intrinsic value source
AI estimate
Next earnings
Jan 29, 2027
Next earnings is estimate
Yes
Company name
added: Ryan Specialty
Sector
added: Specialty insurance brokerage
About
added: Ryan Specialty Holdings, Inc. (Ryan Specialty) is a specialty insurance firm. It works as a wholesale broker for retail insurance brokers, places risks with insurers through binding authority, and acts as a managing underwriter with authority that insurers delegate to it. It earns commissions and fees, and it does not take insurance risk itself. Total revenue was $2,501.8 million in the first nine months of 2026. Patrick G. Ryan founded the firm in 2010 and is its Executive Chairman. The public owns Class A shares, and other holders own LLC Common Units that they can exchange for Class A shares. Ryan Specialty reports in US dollars, and its Class A shares trade on the NYSE.
Thesis
added: The market weighs the strong record of Ryan Specialty against slower growth in a more difficult insurance market. Organic revenue growth fell to 4.0% in Q3 2026, from 15.0% in Q3 2025, as most casualty lines grew but the property portfolio declined. Debt also rose to $3.7 billion as Ryan Specialty bought back shares and made acquisitions. The AI estimate uses a multiple of 2027 adjusted earnings per share. For the price to rise, three things must be true. Organic growth must stay in the mid-single digits or rise, as more risks move to the specialty market. The Empower program must give the savings that Ryan Specialty expects, about $80 million a year by 2029, so that the adjusted EBITDAC margin stops falling. Share buybacks and acquisitions must add to adjusted earnings per share while debt stays at a level the firm can carry. The Q4 2026 results and the 2027 outlook, expected about January 29, 2027, are the next test, and the results of 2027 show the trend. If the property business declines more or casualty growth slows, the price can stay low.
Valuation
added: The intrinsic value for Ryan Specialty is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the filings of Ryan Specialty. The method is a multiple of adjusted diluted earnings per share (EPS) for 2027, less the liability under the tax receivable agreement per share. Adjusted EPS leaves out the amortization of acquired intangible assets, changes in contingent consideration, restructuring costs and some equity-based pay, and it counts all LLC Common Units as exchanged for Class A shares. The Q3 2026 results (Form 8-K of October 29, 2026) give adjusted diluted EPS of $0.51 for Q3 2026 and $1.75 for the first nine months, on an adjusted diluted share count of 266.3 million for Q3. The Q4 2025 results of February 12, 2026 give adjusted diluted EPS of $0.45 for Q4 2025 and $1.96 for 2025. The estimate assumes 2026 adjusted EPS of about $2.22: $1.75 for the first nine months plus about $0.47 for Q4. Because EPS is after interest, the estimate makes no separate debt adjustment. The Form 10-Q gives debt principal of $3,693.1 million and cash and cash equivalents of $168.8 million at September 30, 2026. It also gives tax receivable agreement liabilities of $454.4 million, which the estimate subtracts at $1.71 per share. The cover of the Form 10-Q gives 119,694,115 Class A shares and 131,887,106 Class B shares at October 26, 2026. Each Class B share goes with an LLC Common Unit that its holder can exchange for a Class A share. The 2027 adjusted EPS and the multiples are assumptions. The low case assumes adjusted EPS of $2.20, because insurance prices fall and organic growth stays low, at 16 times. It gives $33.49 per share. The base case assumes $2.40, about 8% more than in 2026, with savings from the Empower program and share buybacks, at 20 times. It gives $46.29 per share. The high case assumes $2.60 at 24 times. It gives $60.69 per share. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $46.69 per share. Ryan Specialty is a large wholesale broker and managing underwriter. Retail brokers and insurers depend on its specialists, its access to many insurance markets and the authority that insurers delegate to it, and these relations take years to build. These give an advantage that can last 10 years or more. But other wholesale brokers compete for the same business, and brokers can leave and take clients with them. The estimate uses no results after September 30, 2026. As of Nov 14, 2026.
Risks
added: Commissions depend on insurance prices and on the flow of risks to the specialty market. Organic growth fell to 4.0% in Q3 2026 from 15.0% a year earlier, and the property portfolio declined. Debt principal was $3,693.1 million at September 30, 2026, and $422.8 million was drawn on the revolving credit facility. The term loan has a floating rate. The tax receivable agreement liabilities were $454.4 million at September 30, 2026, and exchanges of LLC Common Units can increase them. Brokers and underwriters are the main asset. If key people leave for competitors, they can take clients and insurer relations with them. Holders of LLC Common Units own about half of the firm and can exchange them for Class A shares and sell them.
Balance sheet
added: Cash: $169M Debt: $3.7B Net debt: $3.5B EBITDA, last 12 months: $1.0B Net debt / EBITDA: 3.4× (medium) Undrawn credit line: $977M Debt due within 12 months: $42M Last debt due: 2032 At September 30, 2026, debt principal was $3,693.1 million: a term loan of $1,670.3 million, $422.8 million drawn on the revolving credit facility, $400.0 million of senior secured notes due 2030 and $1,200.0 million of senior secured notes due 2032. Cash and cash equivalents were $168.8 million, and $977.2 million of the revolving credit facility was available. Adjusted EBITDAC was $1,025.7 million in the 12 months to September 30, 2026: $222.3 million in Q4 2025 and $803.4 million in the first nine months of 2026. Fiduciary cash and receivables of $4,935.4 million belong to clients and insurers and equal the fiduciary liabilities. Tax receivable agreement liabilities were $454.4 million. In the first nine months of 2026, Ryan Specialty returned over $500 million to shareholders through dividends, distributions and share repurchases, and $150.0 million of authorization remained at September 30, 2026. As of Sep 30, 2026.
Checkpoints
added: Jan 29, 2027 (estimate): Q4 2026 results: organic growth. Pending. Watch: Organic revenue growth for Q4 2026 is 4% or more and adjusted diluted earnings per share are above the $0.45 of Q4 2025, and this passes; lower growth or lower earnings per share fails. 2027 (estimate): 2027 margin and Empower savings. Pending. Watch: The adjusted EBITDAC margin for 2027 is equal to or above the margin for 2026, and this passes; a lower margin fails.
Recent events
added: Oct 29, 2026: Ryan Specialty reported Q3 2026 results. Total revenue grew 4.7% to $790.0 million, with organic growth of 4.0%. Adjusted EBITDAC grew 3.8% to $244.4 million, and adjusted diluted earnings per share grew 8.5% to $0.51. It repurchased $150.0 million of Class A shares and declared a quarterly dividend of $0.13 per share. Jul 30, 2026: Ryan Specialty reported Q2 2026 results. Total revenue grew 7.2% to $916.6 million, with organic growth of 6.7%, and adjusted diluted earnings per share grew 12.1% to $0.74. It repurchased $260.0 million of Class A shares in the quarter. May 26, 2026: The board increased the share repurchase authorization by $300 million, after the company used the prior $300 million authorization. Apr 30, 2026: Ryan Specialty reported Q1 2026 results, with revenue growth of 15.2% to $795.2 million and organic growth of 11.8%. It also agreed that a trust of Patrick G. Ryan will sell it shares when employees exercise new stock options, so that the options do not add shares. Feb 12, 2026: Ryan Specialty reported Q4 2025 results, with organic growth of 6.6% and adjusted diluted earnings per share of $0.45. It announced a $300 million share repurchase authorization and the Empower restructuring program, which should cost about $160 million and save about $80 million a year in 2029.